Persistent progress.
expert_opinion · Level V
Where this comes from
- Record sourced from PubMed, PMID 34562365.
- Also identified by DOI 10.1016/j.cell.2021.08.006 and PMC identifier 8462135.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The highly effective and safe mRNA-based severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines draw on decades of painstaking research to overcome the many hurdles for delivering, expressing, and avoiding toxicity of therapeutic mRNA. Cell editor Nicole Neuman talked with Dr. Katalin Karikó and Dr. Drew Weissman, recipients of the 2021 Lasker∼DeBakey Clinical Medical Research Award, to learn more about their quest to develop mRNA-based therapeutics, which led them to the crucial discovery that modification of mRNA could prevent toxicity and increase expression. This conversation has been adapted for print below, with editing for clarity, accuracy, and length.
Medical subject headings
- Biotechnology
- COVID-19
- COVID-19 Vaccines
- RNA, Messenger
- SARS-CoV-2
- Vaccines, Synthetic